期刊文献+

胆宁片对胆汁瘀积小鼠肝脏转运体及代谢酶基因表达的影响 被引量:6

Regulation of genes expression of hepatic transporters and metabolic enzymes in extrahepatic cholestasis mice by Danning Tablets
在线阅读 下载PDF
导出
摘要 目的探讨胆宁片(大黄、虎杖、青皮、白茅根、陈皮、郁金、山楂)对胆管结扎所致胆汁瘀积小鼠的保护作用及机制。方法将58只小鼠随机分为5组,分别为假手术组,胆管结扎模型组,胆宁片6、3、1.5 g/kg 3个剂量组,观察各组小鼠肝功能各项生化指标和肝组织病理学改变,并采用RT-PCR方法,检测多药耐药相关蛋白3(MRP3)、钠离子-牛磺胆酸协同转运蛋白(NTCP)、多药耐药蛋白2(MDR2)、谷胱甘肽-S-转移酶A1(GSTA1)和葡萄糖醛酸转移酶1A1(UGT1A1)mRNA水平的变化。结果与假手术组比较,胆管结扎模型组小鼠血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总胆红素(TB)、直接胆红素(DB)、总胆汁酸(TBA)、γ-三磷酸鸟苷(γ-GTP)均明显升高(P<0.01),组织病理学变化明显,NTCP表达明显降低(P<0.05),GSTA1,MRP3 mRNA表达明显升高(P<0.05或P<0.01),UGT1A1和MDR2表达未见明显变化。与模型组比较,胆宁片处理组可明显降低小鼠血清中ALT、AST、ALP、TB、DB的升高(P<0.05或P<0.01),且表现出剂量相关性。胆宁片6 g/kg剂量组可明显改善组织病理学变化,上调上述所有基因的mRNA表达(P<0.05或P<0.01)。但胆宁片各处理组对小鼠血清中TBA和γ-GTP无明显影响。结论胆宁片能有效改善胆管结扎小鼠的胆汁瘀积、肝功能及减轻病理损害,其作用机制可能与上调NTCP、MRP3、GSTA1、UGT1A1和MDR2的表达,减少胆汁酸在肝脏中的蓄积有关。 AIM To investigate the effect and mechanism of Danning Tablets(Rhei Radix et Rhizoma,Polygoni cuspidate Rhizoma et Radix,Citri reticulatae Pericaprium viride,Imperatae Rhizoma,Citri reticulatae Pericarpium,Curcumae Radix,Crataegi Fructus) on mice with extrahepatic cholestasis reproduced by bile duct ligation.METHODS Fifty-eight male ICR mice were randomly assigned into five groups: sham-operated group,bile duct ligation model group,Danning Tablets of 6,3,1.5 g/kg groups treated with bile duct ligation.Liver function and pathological changes of hepatic tissue were examined.Real-time fluorescent quantitative RT-PCR was used to detect the mRNA levels of the multidrug resistance-associated protein 3(MRP3),Na+-dependent taurocholate co-transporting polypeptide(NTCP),multidrug resistance protein 2(MDR2),glutathione-S transferase A1(GSTA1),Uridine diphosphate-5-glucuronosyltransferase 1A1(UGT1A1).RESULTS Compared with sham-operated group,serum levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP),total bilirubin(TB),direct bilirubin(DB),total bile acid(TBA) and γ-glutamyl transpeptidase(γ-GTP) significantly increased in bile duct ligation model group(P0.01).Pathological changes of hepatic tissue were obvious.The mRNA level of NTCP down-regulated(P0.05).The expressions of GSTA1 and MRP3 up-regulated(P0.05 or P0.01),and the expressions of UGT1A1 and MDR2 remained uninfluenced.Compared with bile duct ligation model group,Danning Tablets groups significantly decreased serum levels of ALT,AST,ALP,TB,DB(P0.05 or P0.01) in a dose-dependent manner.After Danning Tablets of 6 g/kg treatment,pathological injuries were relieved and the gene expressions of NTCP,GSTA1,MRP3,UGT1A1 and MDR2 were higher than those of bile duct ligation model group(P0.05 or P0.01).Danning Tablets groups did not alter serum levels of TBA and γ-GTP.CONCLUSION Danning Tablets could improve liver function and relieve hepatic pathological damage of mice with bile duct ligation.Their mechanism may be related to up-regulate the mRNA expressions of MRP3,NTCP,MDR2,GSTA1,UGT1A1 in liver and attenuate the accumulation of bile acids in hepatocytes.
出处 《中成药》 CAS CSCD 北大核心 2013年第7期1385-1389,共5页 Chinese Traditional Patent Medicine
基金 上海市科学技术委员会科研计划项目(10DZ1970200 12QH1402200) 上海市卫生系统优秀青年人才计划(XYQ2011061)
关键词 胆宁片 胆管结扎 肝外胆汁瘀积 转运体 Danning Tablets bile duct ligation extrahepatic chlolestasis transporters
作者简介 王莉(1989-),女,硕士,主要从事中药药效物质基础研究。Tel:13917795435,E-mail:w119890117@126.com 通信作者:王峥涛(1956-),教授,博士,主要从事中药药效物质基础研究。Tel:(021)51322519,E-mail:wangzht@hotmail.com
  • 相关文献

参考文献15

  • 1季光,范建高,陈建杰,陆伦根,邢练军,郑培永,顾宏刚,魏华凤,尤圣富,朱培庭.胆宁片治疗非酒精性脂肪性肝病的多中心随机对照临床研究(英文)[J].中西医结合学报,2008,6(2):128-133. 被引量:21
  • 2路夷平,唐亮.胆宁片治疗慢性胆道感染、胆石症的疗效及安全性分析[J].上海医药,2008,29(3):128-130. 被引量:9
  • 3Ding L L, Zhang B F, Dou W, et al. Protective effect of Dan-ning Tablet on acute liver injury with cholestasis induced by a-naphthylisothiocyanate in rats [ J ]. J Ethnopharmacol, 2012,140(2) : 222-229.
  • 4Glaser S S, Gaudio E, Miller T, et al. Cholangiocyte prolifera-tion and liver fibrosis [ J ]. Expert Rev Mol Med,2009,25(11): el.
  • 5Trauner M,Boyer J L. Bile salt transporters : molecular charac-terization ,function,and regulation[ J]. Physiol Rev,2003,83(2) : 633-671.
  • 6Watanabe N,Takashimizu S, Kojima S,et al. Clinical andpathological features of a prolonged type of acute intrahepaticcholestasis[ J]. Hepatol Res, 2007, 37(8) : 598-607.
  • 7Hofmann A F, Cholestatic liver disease: Pathophysiology andtherapeutic options[ J]. Liver,2002, 22 ( suppl 2) : 14-19.
  • 8张国强,周燕,魏玉辉,朱琳,武新安.茵栀黄颗粒对胆管结扎大鼠肝细胞膜转运体Mrp2、Ntcp及Bsep表达的影响[J].中成药,2012,34(9):1644-1648. 被引量:11
  • 9Angela L S, Katryn A, Jennifer M, et al. Regulation of trans-porter expression in mouse liver, kidney, and intestine duringextrahepatic cholestasis [ J ]. Biochimica et Biophysica Acta,2007,1768; 637-647.
  • 10Yoshitaka H, Shuichi K, Hirokazu T, et al. Altered expressionof nuclear receptors affects the expression of metabolic enzymesand transporters in a rat model of cholestasis [ J]. Biol Pharm,Bull, 2009,32(12) : 2046-2052.

二级参考文献55

  • 1刘延奎,单振武,徐晓光.茵栀黄颗粒的急性毒性和保肝作用研究[J].齐鲁药事,2004,23(6):49-50. 被引量:7
  • 2李贵海,朱建伟,吴丽丽.茵栀黄颗粒的保肝作用研究[J].中药材,2001,24(5):353-355. 被引量:16
  • 3朱培庭,张静哲,王以实,高炬.胆宁片、胆通、熊去氧胆酸治疗慢性胆道感染、胆石病的临床疗效对照研究[J].中国中西医结合外科杂志,1995,1(4):205-209. 被引量:25
  • 4范建高 刘厚钰.胆宁片治疗非酒精性脂肪肝的多中心临床研究[J].美国中华医药杂志,2000,6:32-34.
  • 5王兰兰,吴健民.临床免疫学与检验[M].北京:人民卫生出版社,2008:227.
  • 6刘世 刘海波.胆宁片结合胆肠Roux—en—Y吻合术治疗肝胆管结石临床观察[J].中华中西医杂志,2004,24(9):366-366.
  • 7Oneta CM, Dufour JF. Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly. 2002; 132 (35-36): 493-505.
  • 8Tagle Arrospide M. Non-alcoholic fatty liver. Rev Gastroenterol Peru. 2003; 23(1): 49-57.
  • 9Alba LM, Lindor K. Non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2003;17(8):977-986.
  • 10Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002; 17: 186-190.

共引文献37

同被引文献72

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部